Page 2020 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 118 Hemapheresis 1791

TPE specifically in recurrent focal segmental glomerulosclerosis, the Writing Committee of the American Society for Apheresis: the sixth
especially when it occurs post renal transplantation. It has been special issue. J Clin Apher 28(3):145–284, 2013.
attempted with marginal success in severe refractory vasculitides such 17. George JN, Nester CM: Syndromes of thrombotic microangiopathy.
as Henoch-Schönlein purpura, Kawasaki disease and ANCA- N Engl J Med 371:654–666, 2014.
associated vasculitides. 32 18. Nguyen L, Li X, Duvall D, et al: Twice-daily plasma exchange for patients
with refractory thrombotic thrombocytopenic purpura: the experience of
the Oklahoma Registry, 1989 through 2006. Transfusion 48(2):349–357,
REFERENCES 2008.
19. Bruckert E: Recommendations for the management of patients with
1. Abel JJ, Rowntree LG, Turner BB: Plasma removal with return of homozygous familial hypercholesterolaemia: overview of a new Euro-
corpuscles (plasmaphaeresis). The Journal of Pharmacology and experi- pean Atherosclerosis Society consensus statement. Atheroscler Suppl
mental therapeutics Vol. V. No. 6, July, 1914. Transfus Sci 11(166):1990. 15(2):26–32, 2014.
2. Whitaker BL, Henry RA: The 2011 National Blood Collection and 20. Hudgins LC, Kleinman B, Scheuer A, et al: Long-term safety and effi-
Utilization Survey Report, Washington DC, 2011, US Department of cacy of low-density lipoprotein apheresis in childhood for homozygous
Health and Human Services. familial hypercholesterolemia. Am J Cardiol 102(9):1199–1204, 2008.
3. Kato GJ, Gladwin MT, Steinberg MH: Deconstructing sickle cell 21. Kolansky DM, Cuchel M, Clark BJ, et al: Longitudinal evaluation and
disease: reappraisal of the role of hemolysis in the development of clinical assessment of cardiovascular disease in patients with homozygous familial
subphenotypes. Blood Rev 21(1):37–47, 2007. hypercholesterolemia. Am J Cardiol 102(11):1438–1443, 2008.
4. Howard J, Malfroy M, Llewelyn C, et al: The Transfusion Alternatives 22. Lefaucheur C, Nochy D, Andrade J, et al: Comparison of combination
Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment
controlled, multicentre clinical trial. Lancet 381(9870):930–938, 2013. of antibody-mediated rejection. Am J Transplant 9(5):1099–1107, 2009.
5. Rombout-Sestrienkova E, Nieman FH, Essers BA, et al: Erythrocytapher- 23. Akalin E, Dinavahi R, Friedlander R, et al: Addition of plasmapheresis
esis versus phlebotomy in the initial treatment of HFE hemochromatosis decreases the incidence of acute antibody-mediated rejection in sensitized
patients: results from a randomized trial. Transfusion 52(3):470–477, patients with strong donor-specific antibodies. Clin J Am Soc Nephrol
2012. 3(4):1160–1167, 2008.
6. De Santis GC, de Oliveira LC, Romano LG, et al: Therapeutic leuka- 24. Llufriu S, Castillo J, Blanco Y, et al: Plasma exchange for acute attacks of
pheresis in patients with leukostasis secondary to acute myelogenous CNS demyelination: Predictors of improvement at 6 months. Neurology
leukemia. J Clin Apher 26(4):181–185, 2011. 73(12):949–953, 2009.
7. Chang MC, Chen TY, Tang JL, et al: Leukapheresis and cranial irra- 25. Agreda-Vasquez GP, Espinosa-Poblano I, Sanchez-Guerrero SA, et al:
diation in patients with hyperleukocytic acute myeloid leukemia: no Starch and albumin mixture as replacement fluid in therapeutic plasma
impact on early mortality and intracranial hemorrhage. Am J Hematol exchange is safe and effective. J Clin Apher 23(5):163–167, 2008.
82(11):976–980, 2007. 26. Vasu S, Leitman SF, Tisdale JF, et al: Donor demographic and laboratory
8. Klamova H, Markova M, Moravcova J, et al: Response to treatment predictors of allogeneic peripheral blood stem cell mobilization in an
in women with chronic myeloid leukemia during pregnancy and after ethnically diverse population. Blood 112(5):2092–2100, 2008.
delivery. Leuk Res 33(11):1567–1569, 2009. 27. Pulsipher MA, Chitphakdithai P, Logan BR, et al: Acute toxicities of
9. Vernia P, D’Ovidio V, Meo D: Leukocytapheresis in the treatment of unrelated bone marrow versus peripheral blood stem cell donation:
inflammatory bowel disease: Current position and perspectives. Transfus results of a prospective trial from the National Marrow Donor Program.
Apher Sci 43(2):227–229, 2010. Blood 121(1):197–206, 2013.
10. Thanaraj S, Hamlin PJ, Ford AC: Systematic review: granulocyte/ 28. Pulsipher MA, Chitphakdithai P, Logan BR, et al: Lower risk for serious
monocyte adsorptive apheresis for ulcerative colitis. Aliment Pharmacol adverse events and no increased risk for cancer after PBSC vs BM
Ther 32(11–12):1297–1306, 2010. donation. Blood 123(23):3655–3663, 2014.
11. Yamamoto T, Umegae S, Matsumoto K: Daily granulocyte and monocyte 29. DiPersio JF, Micallef IN, Stiff PJ, et al: Phase III prospective random-
adsorptive apheresis in patients with active ulcerative colitis: a prospective ized double-blind placebo-controlled trial of plerixafor plus granulocyte
safety and feasibility study. J Gastroenterol 46(8):1003–1009, 2011. colony-stimulating factor compared with placebo plus granulocyte
12. Knobler R, Berlin G, Calzavara-Pinton P, et al: Guidelines on the use colony-stimulating factor for autologous stem-cell mobilization and
of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 28(Suppl transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol
1):1–37, 2014. 27(28):4767–4773, 2009.
13. Flowers ME, Apperley JF, van Besien K, et al: A multicenter prospective 30. Bilgin YM, Visser O, Beckers EA, et al: Evaluation of Dutch guideline for
phase 2 randomized study of extracorporeal photopheresis for treatment just-in-time addition of plerixafor to stem cell mobilization in patients
of chronic graft-versus-host disease. Blood 112(7):2667–2674, 2008. who fail with granulocyte-colony-stimulating factor. Transfusion 2014.
14. Jaksch P, Knobler R: ECP and solid organ transplantation. Transfus Apher 31. Clayton JA, Vitale S, Kim J, et al: Prevalence of posterior subcapsular
Sci 50(3):358–362, 2014. cataracts in volunteer cytapheresis donors. Transfusion 51(5):921–928,
15. Kuzmina Z, Stroncek D, Pavletic SZ: Extracorporeal photopheresis as a 2011.
therapy for autoimmune diseases. J Clin Apher 30:224–237, 2015. 32. Kim YA, Sloan SR: Pediatric therapeutic apheresis: rationale and indica-
16. Schwartz J, Winters JL, Padmanabhan A, et al: Guidelines on the use of tions for plasmapheresis, cytapheresis, extracorporeal photopheresis, and
therapeutic apheresis in clinical practice-evidence-based approach from LDL apheresis. Pediatr Clin North Am 60:1569–1580, 2013.